SCHEMBL4121612

SCHEMBL4121612

CCOc1nn2c(-c3ccc(F)cc3)c(-c3ccccc3Cl)cnc2c1C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
KMT2A Q03164 2/20 0.37
RXFP1 Q9HBX9 2/20 0.36
TP53 P04637 2/20 0.36
KDM4C Q9H3R0 2/20 0.36
CTSA P10619 1/20 0.36
ALDH1A1 P00352 3/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GPR119 Q8TDV5 1/20 0.35
BACE1 P56817 1/20 0.35
GAA P10253 3/20 0.35
KDM4E B2RXH2 2/20 0.35
ALOX15 P16050 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
AKT1 P31749 1/20 0.35
AKT2 P31751 1/20 0.35
MDM2 Q00987 1/20 0.35
SSTR5 P35346 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4112658 0.91 ALDH1A1 (0.43) L3MBTL1KMT2ARXFP1TP53ALDH1A1
SCHEMBL2085454 0.83 RXFP1 (0.38) KMT2ARXFP1TP53ALDH1A1GPR119
SCHEMBL4114844 0.80 ALDH1A1 (0.42) L3MBTL1KMT2ARXFP1TP53ALDH1A1
SCHEMBL2086350 0.80 PTGS2 (0.39) KMT2AKDM4CALDH1A1BACE1MEN1
SCHEMBL4107563 0.79 TP53 (0.40) KMT2ARXFP1TP53ALDH1A1GPR119
SCHEMBL2085969 0.79 ALDH1A1 (0.41) L3MBTL1KMT2ARXFP1TP53ALDH1A1
SCHEMBL2084104 0.79 ALDH1A1 (0.39) L3MBTL1KMT2ARXFP1TP53ALDH1A1
SCHEMBL2086709 0.78 CYP1A2 (0.45) KMT2AALDH1A1GAAKDM4EALOX15
SCHEMBL4128916 0.77 LMNA (0.51) L3MBTL1KMT2ARXFP1TP53ALDH1A1
SCHEMBL4124245 0.77 NPC1 (0.43) KMT2ARXFP1TP53ALDH1A1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD PDE10A 573/4885L3MBTL1 3941/4885KMT2A 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.